GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome
Publication: biomedcentral.com | Publication Date: 06 March 2025 Authors: Jagomäe, T., Velling, S., Tikva, T.B. et al. Abstract Wolfram syndrome (WS) is a rare autosomal disorder caused by WFS1 gene mutations, currently lacking approved treatments. Preclinical and clinical reports suggest that diabetes medications, such as glucagon-like peptide-1 receptor agonist (GLP1-RA), slow WS-related diabetes and neurodegeneration, […]
You must be logged in to post a comment.